. Author manuscript; available in PMC: 2011 Nov 16.

Published in final edited form as: Arch Phys Med Rehabil. 2010 May;91(5):816–831. doi: 10.1016/j.apmr.2010.01.022

Table 5.

Cannabinoids for Post-SCI Pain

Author Year Country Score (PEDro/D&B)	Population	Intervention	Results
Hagenbach et al.2007⁷⁰ Switzerland RCT (Phase 3) PEDro=4	N:13 Type of pain: Spastic pain	Treatment: In a double blind manner, SCI patients from phase 1 of the study were randomly assigned to either maximum oral THC doses (6 participants) or placebo doses (7 participants) for 6 weeks. Pain Scale: Self ratings	No significant improvement in pain post SCI was seen compared to placebo on day 8 and 43. Individuals in the oral THC group showed no significant difference in mood or attention compared to the placebo group or to baseline.
Hagenbach et al., 2007⁷⁰ Switzerland Pre-Post (Phase 1) D&B=16	N:22 Type of pain: Spastic pain	Treatment: Patients received 10mg oral THC on day 1. Dose titration began on day 2 until the maximum tolerated dose or treatment aim was achieved and maintained for 6 weeks. Pain Scale: Self ratings	Significant improvement in pain was seen on day 1 compared to baseline measures (p=0.047).

Abbreviations: D&B = Downs and Black quality assessment scale score²⁷; EDro = Physiotherapy Evidence Database rating scale score²⁶